Virtu KCG Holdings’s TG Therapeutics TGTX Stock Holding History

Virtu KCG Holdings’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$300K	Sell	29,815 -56,001	-65%	-$627K	0.01%	1671
2017 Q1	$1M	Buy	85,816 +46,992	+121%	+$337K	0.03%	709
2016 Q4	$181K	Buy	38,824 +27,876	+255%	+$163K	﹤0.01%	2656
2016 Q3	$85K	Sell	10,948 -32,378	-75%	-$208K	﹤0.01%	2673
2016 Q2	$263K	Buy	+43,326	New	+$352K	0.01%	2026
2015 Q4	–	Sell	-33,968	Closed	-$342K	–	3930
2015 Q3	$342K	Buy	33,968 +18,331	+117%	+$273K	0.01%	1929
2015 Q2	$259K	Buy	+15,637	New	+$248K	﹤0.01%	2263
2014 Q4	–	Sell	-17,078	Closed	-$182K	–	4229
2014 Q3	$182K	Buy	+17,078	New	+$158K	﹤0.01%	2965

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Virtu KCG Holdings's TGTX Position: Q2 2017 in Review

Virtu KCG Holdings reduced its TG Therapeutics (TGTX) stake by 65% in Q2 2017, selling an estimated $627K and leaving 29,815 shares worth $300K. The position accounts for 0.01% of the portfolio, ranked #1671.

Virtu KCG Holdings first reported a position in TGTX in Q3 2014 and has held it in 8 quarters since. The position peaked at $1M in Q1 2017. 106 funds tracked by Wall St. Rank hold TGTX as of Q2 2017.

Virtu KCG Holdings held 29,815 shares of TG Therapeutics worth $300K as of Q2 2017.
Virtu KCG Holdings sold 56,001 TG Therapeutics shares in Q2 2017, an estimated $627K.
TG Therapeutics made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1671 holding.
Virtu KCG Holdings first reported a position in TG Therapeutics in Q3 2014 and has held it in 8 quarters since.
Virtu KCG Holdings's TG Therapeutics position peaked at $1M in Q1 2017.
106 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.